^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    LAG3 mutation

    i
    Other names: LAG3, Lymphocyte Activating 3, Lymphocyte Activation Gene 3 Protein, Lymphocyte-Activation Gene 3, CD223 Antigen, CD223, LAG-3, FDC
    Entrez ID:
    3902
    Related biomarkers:
    Expression
    Others
    6ms
    Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity. (PubMed, J Immunol)
    Finally, we demonstrate that a therapeutic LAG3 Ab, C9B7W, which does not block LAG3 interaction with its cognate ligand MHC class II, disrupts LAG3 dimerization and its association with the TCR/CD3 complex. These studies highlight the functional importance of LAG3 dimerization and offer additional approaches to therapeutically target LAG3.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
    |
    LAG3 expression • LAG3 mutation
    8ms
    Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function. (PubMed, Proc Natl Acad Sci U S A)
    Intriguingly, we showed that antibodies directed against D1, D2, and D3 domains are all capable of blocking LAG-3 dimer formation and MHCII and FGL-1 ligand binding, suggesting a potential allosteric model of LAG-3 function tightly regulated by dimerization. Furthermore, our work reveals unique epitopes, in addition to D1, that can be targeted for immunotherapy of cancer and other human diseases.
    Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • FGL1 (Fibrinogen Like 1)
    |
    LAG3 mutation